Test Id : CPAPD
Conventional Smear-Diagnostic, Varies
Useful For
Suggests clinical disorders or settings where the test may be helpful
Screening for cervical carcinoma and a number of infections of the female genital tract including human papillomavirus, herpes, Candida, and Trichomonas
Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.
| Test Id | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| CVSPC | Physician Interp Conventional | No | No |
Method Name
A short description of the method used to perform the test
Light Microscopy
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
Cervical Papanicolaou Smear, Diagnostic
CPAPD
Pap Smear
Specimen Type
Describes the specimen type validated for testing
Varies
Ordering Guidance
Laboratory approval prior to ordering cytology testing is required
Specimen submitted as endocervical curettage or endocervical brushing must be ordered as CYTNG/ Cytology Non-Gynecologic.
Necessary Information
1. An acceptable cytology request form must accompany specimen containers and include the following: Patient's name, medical record number, date of birth, sex, source (exact location and procedure used), date specimen was taken, name of ordering physician and pager number.
2. Submit any pertinent clinical information, including date of last menstrual period.
ORDER QUESTIONS AND ANSWERS
| Question ID | Description | Answers |
|---|---|---|
| CY037 | Pap Smear Test |
Cervical/Endocervical Vaginal |
| CY038 | Clinical History | |
| CY039 | Menstrual Status (LMP, PM, Pregnant) | |
| CY040 | Hormone Therapy/Contraceptives |
None/Not known Oral Contraceptives Depoprovera IUD Hormone Replacement Therapy |
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Patient Preparation: For optimal interpretation, Papanicolaou smears should be collected near the middle of the menstrual cycle. No douching, lubricant use, or sexual intercourse for 24 hours prior to specimen collection.
Container/Tube: Slide
Specimen Volume: Circular scrape of cervical os
Collection Instructions:
1. Specimen containers must be labeled with a minimum of 2 unique identifiers (patient's name, and medical record number or date of birth). Containers should also be labeled with specimen source, and date collected.
2. Glass slides may be labeled with a single unique identifier, but 2 identifiers are preferred. If multiple slides are submitted, each slide must have proper identification. Glass slides should be identified with the patient's name and a second patient identifier that is also on the accompanying paperwork (ie, medical record number or date of birth)
3. Fix slides immediately in 95% alcohol or treat with commercially available spray fixative.
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Forms
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| SurePath vial | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Ambient (preferred) | SLIDE | |
| Refrigerated | SLIDE | ||
Useful For
Suggests clinical disorders or settings where the test may be helpful
Screening for cervical carcinoma and a number of infections of the female genital tract including human papillomavirus, herpes, Candida, and Trichomonas
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Squamous cell carcinoma of the cervix is believed to develop in progressive stages from normal through precancerous (dysplastic) stages, to carcinoma in situ, and eventually invasive carcinoma. This sequence is felt to develop over a matter of years in most patients.
The etiology of cervical carcinoma is unknown, but the disease is believed to be related to sexual activity and possibly sexually transmitted viral infections such as human papillomavirus (HPV).
Most cervical carcinomas and precancerous conditions occur in the transformation zone (squamo-columnar junction), therefore, this area needs to be sampled if optimum results are to be obtained.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Satisfactory for evaluation. Negative for intraepithelial lesion or malignancy.
Note: Abnormal results will be reviewed by a physician at an additional charge.
Interpretation
Provides information to assist in interpretation of the test results
Standard reporting, as defined by the Bethesda System (TBS) is utilized.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
If endocervical cells have not been obtained (less than optimal smears) the results may be unreliable.
There is a false-negative rate of 10% to 20% in the presence of cervical intraepithelial neoplasia or invasive squamous cell carcinoma.
The Papanicolaou test is unreliable for endometrial carcinoma (at least 50% false-negative rate).
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Wright TC Jr, Cox JT, Massad LS, et al: ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002 April;287(16):2120-2129
2. Solomon D, Davey D, Kurman R, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology-Consensus Statement JAMA. 2002 April;287(16):2114-2119
Method Description
Describes how the test is performed and provides a method-specific reference
Papanicolaou-stained slides are microscopically examined by a cytotechnologist. Abnormal findings are reviewed and reported by a pathologist (charged separately).(Unpublished Mayo method)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
P3000
88164
88141-CVSPC (if appropriate)
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| CPAPD | Conventional Smear-Diagnostic | 47528-5 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 71306 | Interpretation | 59465-5 |
| 71307 | Participated in the Interpretation | No LOINC Needed |
| 71308 | Report electronically signed by | 19139-5 |
| 71309 | Addendum | 35265-8 |
| 71310 | Gross Description | 22634-0 |
| CY037 | Pap Test Source | 19763-2 |
| CY038 | Clinical History | 22636-5 |
| CY039 | Menstrual Status (LMP, PM, Pregnant) | 8678-5 |
| CY040 | Hormone Therapy/Contraceptives | 8659-5 |
| 71573 | Disclaimer | 62364-5 |
| 71819 | Case Number | 80398-1 |